This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

TFF Pharmaceuticals Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Craig Jalbert

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	3.3yrs

Recente managementupdates

Recent updates

Can TFF Pharmaceuticals (NASDAQ:TFFP) Afford To Invest In Growth?

Apr 10

Is TFF Pharmaceuticals (NASDAQ:TFFP) In A Good Position To Deliver On Growth Plans?

Sep 27

CEO

Craig Jalbert (62 yo)

less than a year

Tenure

Mr. Craig R. Jalbert serve as a CEO, President, Chief Financial Officer, Treasurer and Secretary and sole member of the board since November 2024 at TFF Pharmaceuticals, Inc. He is President, Treasurer, CS...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Craig Jalbert	CEO, President	less than a year	geen gegevens	geen gegevens
Anthony Hickey	Chairman of the Scientific Advisory Board and Senior Research & Development Advisor	1.9yrs	geen gegevens	geen gegevens
David Denning	Member of Scientific Advisory Board	3.3yrs	geen gegevens	geen gegevens
Drew Weissman	Member of Scientific Advisory Board	3.3yrs	geen gegevens	geen gegevens
Ted Ross	Member of Scientific Advisory Board	3.3yrs	geen gegevens	geen gegevens
Mike Saag	Member of Scientific Advisory Board	3.3yrs	geen gegevens	geen gegevens
David Cornfield	Member of Scientific Advisory Board	3.3yrs	geen gegevens	geen gegevens
Jay Peters	Member of Scientific Advisory Board	3.3yrs	geen gegevens	geen gegevens

3.3yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van TFFP wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2024/12/15 04:30
Aandelenkoers aan het einde van de dag	2024/12/12 00:00
Inkomsten	2024/09/30
Jaarlijkse inkomsten	2023/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige regelgevingsformulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Lees hier meer.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op .

Bronnen van analisten

TFF Pharmaceuticals, Inc. wordt gevolgd door 4 analisten. 0 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Mayank Mamtani	B. Riley Securities, Inc.
Raghuram Selvaraju	H.C. Wainwright & Co.
Jason McCarthy	Maxim Group

This company listing is no longer active

TFF Pharmaceuticals Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

TFF Pharmaceuticals, Inc. Appoints Craig R. Jalbert as Chief Financial Officer

TFF Pharmaceuticals, Inc., Annual General Meeting, Jun 04, 2024

TFF Pharmaceuticals, Inc. Appoints Thomas B. King to Board of Directors

TFF Pharmaceuticals, Inc. Appoints Catherine Lee to its Board of Directors

TFF Pharmaceuticals, Inc., Annual General Meeting, Nov 21, 2023

Aaron Fletcher Advises TFF Pharmaceuticals, Inc. of His Decision Not to Stand for Reelection to the Board

Recent updates

TFF Pharmaceuticals, Inc.(NasdaqCM:TFFP) dropped from NASDAQ Composite Index

Nasdaq Determines to Delist Common Stock of TFF Pharmaceuticals

TFF Pharmaceuticals, Inc. Appoints Craig R. Jalbert as Chief Financial Officer

New major risk - Share price stability

New major risk - Shareholder dilution

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 77%

TFF Pharmaceuticals, Inc. Provides Continued Positive Outcomes from Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection

Tff Pharmaceuticals, Inc. Provides Regulatory Update on Tacrolimus Inhalation Powder (Tff Tac) Clinical Program for the Prevention of Lung Transplant Rejection

Consensus revenue estimates decrease by 29%, EPS upgraded

TFF Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $2.055 million.

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Tff Pharmaceuticals, Inc. Provides Update on Tacrolimus Inhalation Powder (Tff Tac) Phase 2 Trial for the Prevention of Lung Transplant Rejection

TFF Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $4.787396 million.

TFF Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $4.787396 million.

TFF Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $4.787505 million.

TFF Pharmaceuticals, Inc., Annual General Meeting, Jun 04, 2024

TFF Pharmaceuticals, Inc. Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF Tac) Phase 2 Trial Following Oral Presentation At the Ishlt 44Th Annual Late-Breaking Clinical Science Abstract Sessions

New major risk - Market cap size

TFF Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

Full year 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 39%

No longer forecast to breakeven

TFF Pharmaceuticals, Inc. Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (Tff VORI) Clinical Programs

TFF Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.18 million.

TFF Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.18 million.

TFF Pharmaceuticals, Inc. Announces Update on Clinical Programs

New major risk - Share price stability

TFF Pharmaceuticals, Inc. to Present Data from Phase 2 Trial of Voriconazole Inhalation Powder for the Treatment of Invasive Pulmonary Aspergillosis At the 11Th Advances Against Aspergillosis & Mucormycosis & Mucromycosis Conference

Forecast to breakeven in 2026

New minor risk - Profitability

TFF Pharmaceuticals, Inc. Appoints Thomas B. King to Board of Directors

TFF Pharmaceuticals, Inc. Appoints Catherine Lee to its Board of Directors

TFF Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $35 million.

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 40%

TFF Pharmaceuticals, Inc., Annual General Meeting, Nov 21, 2023

Aaron Fletcher Advises TFF Pharmaceuticals, Inc. of His Decision Not to Stand for Reelection to the Board

Consensus revenue estimates increase by 37%

New major risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 21%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Can TFF Pharmaceuticals (NASDAQ:TFFP) Afford To Invest In Growth?

No longer forecast to breakeven

No longer forecast to breakeven

Key Executive recently bought US$132k worth of stock

Consensus revenue estimates increase by 16%

TFF Pharmaceuticals, Inc. Appoints Harlan Weisman, M.D. as Permanent Chief Executive Officer

TFF Pharmaceuticals, Inc. Appoints Zamaneh Mikhak as Chief Medical Officer

Forecast to breakeven in 2025

Key Executive recently bought US$53k worth of stock

TFF Pharmaceuticals Announces Leadership Transition

Consensus revenue estimates increase by 98%

Third quarter 2022 earnings released: US$0.29 loss per share (vs US$0.34 loss in 3Q 2021)

High number of new and inexperienced directors

Price target decreased to US$16.00

TFF Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

TFF Pharmaceuticals, Inc. Announces Second Patient Successfully Treated with Voriconazole Inhalation Powder Through Compassionate Use Program

TFF Pharmaceuticals Announces Presentation of Data Featuring Applications of Thin Film Freezing Technology at AAPS PharmSci 360 Meeting

Independent Director exercised options and sold US$72k worth of stock

Is TFF Pharmaceuticals (NASDAQ:TFFP) In A Good Position To Deliver On Growth Plans?

TFF Pharmaceuticals Announces Acceptance of Multiple Abstracts Featuring Applications of Thin Film Freezing Technology at the Upcoming AAPS PharmSci 360 Meeting

TFF Pharmaceuticals, Inc., Annual General Meeting, Nov 07, 2022

TFF Pharmaceuticals, Inc. Announces Presentation of Patient Data with Voriconazole Inhalation Powder At the 15Th International Congress on Lung Transplantation

TFF Pharma: The Potential Is Still Very Much Present

Consensus revenue estimates fall by 84%

No longer forecast to breakeven